Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus Compared to Prograf

Vinayak Dhungel, Monica M. Colvin-Adams, Peter M. Eckman

Department of Medicine, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, USA.

DOI: 10.4236/ojots.2013.32004                

Abstract

Calcineurin inhibitors are the cornerstone of solid organ transplant immunosuppression. Tacrolimus has only recently become available in a non-branded formulation, and there is little data on the efficacy and safety of generic tacrolimus, particularly following heart transplant. We performed a retrospective analysis of 21 consecutive patients who were treated with generic tacrolimus following heart transplant and compared rate of biopsy-proven acute cellular rejection to historical controls who were treated with Prograf. No significant difference in biopsy-proven acute cellular rejection was noted between the groups and rates of opportunistic infection and death were comparable. Although limited by the single-center, retrospective design, this preliminary data may be useful to clinicians facing the option of initiating generic tacrolimus following heart transplant.

Keywords

Generic Tacrolimus; Heart Transplant

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. Stehlik, L. B. Edwards, A. Y. Kucheryavaya, P. Aurora, J. D. Christie, R. Kirk, et al., “The Registry of the International Society for Heart and Lung Transplantation: Twenty-Seventh Official Adult Heart Transplant Report—2010,” The Journal of Heart and Lung Transplantation, Vol. 29, No. 10, 2010, pp. 1089-1103. doi:10.1016/j.healun.2010.08.007
[2]	P. A. Uber, H. J. Ross, A. O. Zuckermann, S. C. Sweet, P. A. Corris, K. McNeil, et al., “Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory,” The Journal of Heart and Lung Transplantation, Vol. 28, No. 7, 2009, pp. 655-660. doi:10.1016/j.healun.2009.05.001
[3]	H. A. Abdulnour, C. E. Araya and V. R. Dharnidharka, “Comparison of Generic Tacrolimus and Prograf Drug Levels in a Pediatric Kidney Transplant Program: Brief Communication,” Pediatric Transplantation, Vol. 14, No. 8, 2010, pp. 1007-1011. doi:10.1111/j.1399-3046.2010.01393.x
[4]	J. A. Petan, N. Undre, M. R. First, K. Saito, T. Ohara, O. Iwabe, et al., “Physiochemical Properties of Generic Formulations of Tacrolimus in Mexico,” Transplantation Proceedings, Vol. 40, No. 5, 2008, pp. 1439-1442. doi:10.1016/j.transproceed.2008.03.091